Entries by Peggy Bickerton

Astex Pharmaceuticals Celebrates as Cancer Drug Receives Marketing Approval in Europe

Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives Approval in Europe as a First-Line Treatment for HR+/HER2- locally Advanced or Metastatic Breast Cancer with an Aromatase Inhibitor – Kisqali was discovered as part of a strategic research collaboration under which Astex and Novartis Institutes for BioMedical Research (NIBR) scientists jointly developed and optimised […]

Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor Novartis drug Kisqali® (ribociclib, LEE011) receives marketing approval by the US FDA as a first-line drug for HR+/HER2- advanced breast cancer in combination with an aromatase inhibitor Astex’s scientific expertise […]